Australia - inglés - Department of Health (Therapeutic Goods Administration)

merz australia pty ltd - incobotulinumtoxina, quantity: 100 u - injection, powder for - excipient ingredients: albumin; sucrose - xeomin is indicated in adults for the treatment of:,? cervical dystonia (spasmodic torticollis),? blepharospasm,? spasticity of the upper limb,? chronic sialorrhea due to neurological disorders,? upper facial lines,- glabellar frown lines,- lateral periorbital lines (crow?s feet),- horizontal forehead lines,xeomin is indicated in children and adolescents aged 2 years to 17 years for the symptomatic treatment of:,? chronic sialorrhea due to neurological/neurodevelopmental disorders,? spasticity of the lower and/or upper limbs

Australia - inglés - Department of Health (Therapeutic Goods Administration)

merz australia pty ltd - incobotulinumtoxina, quantity: 50 u - injection, powder for - excipient ingredients: albumin; sucrose - xeomin is indicated in adults for the treatment of:,? cervical dystonia (spasmodic torticollis),? blepharospasm,? spasticity of the upper limb,? chronic sialorrhea due to neurological disorders,? upper facial lines,- glabellar frown lines,- lateral periorbital lines (crow?s feet),- horizontal forehead lines,xeomin is indicated in children and adolescents aged 2 years to 17 years for the symptomatic treatment of:,? chronic sialorrhea due to neurological/neurodevelopmental disorders,? spasticity of the lower and/or upper limbs

Australia - inglés - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alemtuzumab -

Australia - inglés - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alemtuzumab, quantity: 10 mg/ml - injection, concentrated - excipient ingredients: disodium edetate; potassium chloride; monobasic potassium phosphate; sodium chloride; dibasic sodium phosphate heptahydrate; polysorbate 80; water for injections - lemtrada is indicated for the treatment of relapsing forms of multiple sclerosis (ms) for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 10 ml - injection, diluent for - excipient ingredients: - berinert iv is indicated for the treatment of acute attacks in patients with hereditary angioedema (hae).

Australia - inglés - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alemtuzumab, quantity: 30 mg - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections; polysorbate 80; monobasic potassium phosphate; dibasic sodium phosphate heptahydrate; sodium chloride; potassium chloride - the treatment of patients with b-cell chronic lymphocytic leukaemia (cll) who have relapsed after failure of two prior therapies.,mabcampath is indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia (b-cll).

Australia - inglés - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - reteplase -

Australia - inglés - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - c1 esterase inhibitor, quantity: 3000 iu - injection, diluent for - excipient ingredients: - berinert? sc for subcutaneous injection is indicated for prevention of recurrent hereditary angioedema (hae) attacks in patients aged 8 years and older with c1 esterase inhibitor deficiency.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - c1 esterase inhibitor, quantity: 2000 iu - injection, diluent for - excipient ingredients: - berinert? sc for subcutaneous injection is indicated for prevention of recurrent hereditary angioedema (hae) attacks in patients aged 8 years and older with c1 esterase inhibitor deficiency.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - bezlotoxumab -